Here's Why West Pharmaceutical Services (WST) Stock Fell 38%
Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical tensions, and an upcoming announcement on tariffs led to a sharp decline in equities by the end of the first quarter. Investors sought safety, driving U.S. Treasury yields down. The Conestoga Small Cap Composite returned -11.35% (net) in the first quarter compared to the Russell 2000 Growth Index's -11.12% return. The Conestoga SMid Cap Composite returned -5.73% compared to the Russell 2500 Growth Index's -10.80% return. The Conestoga Micro-Cap Composite returned -8.24% vs the Russell Microcap Growth Index's return of -17.75%. Finally, the Conestoga Mid Cap Composite returned 0.96% (net), compared to the Russell Midcap Growth Index's -7.12% return. Please check the top 5 holdings of the fund for a better understanding of their best picks for 2025.
In its first-quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as West Pharmaceutical Services, Inc. (NYSE:WST). West Pharmaceutical Services, Inc. (NYSE:WST) designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products. The one-month return of West Pharmaceutical Services, Inc. (NYSE:WST) was -4.41%, and its shares lost 42.94% of their value over the last 52 weeks. On May 1, 2025, West Pharmaceutical Services, Inc. (NYSE:WST) stock closed at $210.26 per share with a market capitalization of $15.11 billion.
Conestoga Capital Advisors stated the following regarding West Pharmaceutical Services, Inc. (NYSE:WST) in its Q1 2025 investor letter:
"After being a leader in Q4 on optimism that destocking in the industry was nearly complete, West Pharmaceutical Services, Inc. (NYSE:WST) declined during the quarter. Most of the decline was confined to the day they announced their fourth quarter earnings, which sent shares down 38%, the company's largest single-day move in the company's 40+ years of being publicly traded. Fourth quarter results beat street estimates, but 2025 earnings per share guidance were 22% below expectations. WST announced they're walking away from two large contract manufacturing customers (20% of that segment's revenue), and the ramp of SmartDose is going slower than expected. Additionally, WST is reconsidering its path forward with that product."
A closeup of multiple drug containment systems in an array of colors.
West Pharmaceutical Services, Inc. (NYSE:WST) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held West Pharmaceutical Services, Inc. (NYSE:WST) at the end of the fourth quarter, compared to 31 in the third quarter. West Pharmaceutical Services, Inc. (NYSE:WST) generated net sales of $698 million in the first quarter, representing an organic sales increase of 2.1%. While we acknowledge the potential of West Pharmaceutical Services, Inc. (NYSE:WST) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we covered West Pharmaceutical Services, Inc. (NYSE:WST) and shared the list of worst performing stocks in the S&P 500 so far in 2025. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
1 Cash-Producing Stock on Our Watchlist and 2 to Think Twice About
A company that generates cash isn't automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cash flow is valuable, but it's not everything - StockStory helps you identify the companies that truly put it to work. That said, here is one cash-producing company that leverages its financial strength to beat its competitors and two best left off your watchlist. Trailing 12-Month Free Cash Flow Margin: 11.9% A company that manufactured critical equipment for the United States military during World War II, Dover (NYSE:DOV) manufactures engineered components and specialized equipment for numerous industries. Why Should You Sell DOV? Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy Earnings growth underperformed the sector average over the last two years as its EPS grew by just 2.2% annually Free cash flow margin dropped by 3.3 percentage points over the last five years, implying the company became more capital intensive as competition picked up At $174.93 per share, Dover trades at 18.4x forward P/E. If you're considering DOV for your portfolio, see our FREE research report to learn more. Trailing 12-Month Free Cash Flow Margin: 18.1% Founded by Byron Smith, an investor who held over 100 patents, Illinois Tool Works (NYSE:ITW) manufactures engineered components and specialized equipment for numerous industries. Why Is ITW Not Exciting? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Demand will likely be soft over the next 12 months as Wall Street's estimates imply tepid growth of 1.3% Free cash flow margin shrank by 1.8 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive Illinois Tool Works's stock price of $241.83 implies a valuation ratio of 23x forward P/E. Dive into our free research report to see why there are better opportunities than ITW. Trailing 12-Month Free Cash Flow Margin: 25.1% Founded in 1992 as a scientifically-driven alternative to traditional contract research organizations, Medpace (NASDAQ:MEDP) provides outsourced clinical trial management and research services to help pharmaceutical, biotechnology, and medical device companies develop new treatments. Why Could MEDP Be a Winner? Average organic revenue growth of 17.8% over the past two years demonstrates its ability to expand independently without relying on acquisitions Performance over the past five years was turbocharged by share buybacks, which enabled its earnings per share to grow faster than its revenue Returns on capital are climbing as management makes more lucrative bets Medpace is trading at $308.90 per share, or 24.7x forward P/E. Is now the time to initiate a position? See for yourself in our in-depth research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
2 Industrials Stocks to Own for Decades and 1 to Approach with Caution
Even if they go mostly unnoticed, industrial businesses are the backbone of our country. Still, their generally high capital requirements expose them to the ups and downs of economic cycles, and the market seems to be baking in a prolonged downturn as the industry has shed 2.3% over the past six months. This drop was disappointing since the S&P 500 stood firm. The elite companies can churn out earnings growth under any circumstance, however, and our mission at StockStory is to help you find them. On that note, here are two industrials stocks boasting durable advantages and one we're swiping left on. Market Cap: $14.18 billion Started in 1926 as an insulation contractor, APi (NYSE:APG) provides life safety solutions and specialty services for buildings and infrastructure. Why Does APG Worry Us? Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 3.9 percentage points Underwhelming 3% return on capital reflects management's difficulties in finding profitable growth opportunities At $51.54 per share, APi trades at 24.3x forward P/E. Check out our free in-depth research report to learn more about why APG doesn't pass our bar. Market Cap: $69.97 billion Inventing the first forged aluminum truck wheel, Howmet (NYSE:HWM) specializes in lightweight metals engineering and manufacturing multi-material components used in vehicles. Why Should You Buy HWM? Impressive 12.7% annual revenue growth over the last two years indicates it's winning market share this cycle Share repurchases have amplified shareholder returns as its annual earnings per share growth of 40.5% exceeded its revenue gains over the last two years Free cash flow margin grew by 12.6 percentage points over the last five years, giving the company more chips to play with Howmet is trading at $173.73 per share, or 51.2x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it's free. Market Cap: $7.36 billion With a significant portion of its products made from recycled materials, AZEK (NYSE:AZEK) designs and manufactures goods for outdoor living spaces. Why Are We Bullish on AZEK? Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 12.5% over the past two years Share buybacks catapulted its annual earnings per share growth to 56.9%, which outperformed its revenue gains over the last two years Free cash flow margin increased by 8.8 percentage points over the last five years, giving the company more capital to invest or return to shareholders AZEK's stock price of $51.19 implies a valuation ratio of 33.5x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
Business Wire
5 hours ago
- Business Wire
Ares Management Acquires Minority Stake in Plenitude for €2 Billion
LONDON & MILAN--(BUSINESS WIRE)--Ares Management Corporation ('Ares') (NYSE: ARES), a leading global alternative investment manager, announced today that Ares Alternative Credit funds ('Ares Alternative Credit') have entered into a definitive agreement for the acquisition of a 20% stake in Plenitude, a leader in energy transition controlled by Eni, for approximately €2 billion. The consideration implies an enterprise value for Plenitude of over €12 billion. Completion of the transaction is subject to customary regulatory approvals. Plenitude operates in over 15 countries worldwide, integrating a business model that combines over 4 GW of renewable energy production, as well as retail and energy solutions. The company serves more than 10 million customers and manages an extensive network of 21,500 charging points for electric vehicles. 'This transaction underscores the strength of the Ares platform, which leverages experience across its diversified businesses, including asset-based finance and renewables infrastructure, to deliver flexible capital at scale,' said Joel Holsinger, Partner and Co-Head of Alternative Credit at Ares. 'We are excited to support Plenitude as the company executes its growth strategy focused on enduring profitability and positive community impact.' 'Plenitude is an established leader in energy transition, with a differentiated business model and an outstanding track record, and we are delighted to be part of its next phase of growth,' said Stefano Questa, Partner and Co-Head of European Alternative Credit. Stefano Goberti, CEO of Plenitude, said, 'I am pleased to welcome Ares, one of the world's leading investment funds, as a new shareholder in Plenitude. The deal is a further endorsement of the quality of our strategic approach, which combines economic and environmental sustainability in an integrated business model projected on the future of the energy sector. Ares, with its entry into the company, highlights the progression of Plenitude's value and becomes part of our growth journey, which we pursue with determination and conviction day after day.' The Ares Alternative Credit strategy is a leading investor in asset-based finance, managing approximately $42.9 billion in assets under management as of March 31, 2025. The team invests across the capital structure and seeks opportunities in large, diversified portfolios across various sectors, including specialty finance, lender finance, equipment leasing, structured products, net lease, cash flow streams (e.g., royalties, licensing, management fees) and other asset-focused investments. Aligning Ares' investment activities with its social impact, Ares and Ares Alternative Credit portfolio managers have committed to donate a portion of the performance fees from Ares Alternative Credit's Pathfinder family of funds to support global health and education charities. About Ares Management Corporation Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across the credit, real estate, private equity and infrastructure asset classes. We seek to provide flexible capital to support businesses and create value for our stakeholders and within our communities. By collaborating across our investment groups, we aim to generate consistent and attractive investment returns throughout market cycles. As of March 31, 2025, Ares Management Corporation's global platform had approximately $546 billion of assets under management, with operations across North America, South America, Europe, Asia Pacific and the Middle East. For more information, please visit
